OSLO, Norway, Oct. 2, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting data from the Phase 1/2a LYMRIT 37-01 study investigating Betalutin® (177Lu-lilotomab satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma (iNHL) has been accepted for a poster presentation at the 60th Annual Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018, San Diego, CA).
Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin's lymphoma (NHL) - Analysis with 6-month follow-up
Authors: A. Kolstad, et al.
The Company will also have two non-clinical posters: one presenting Betalutin® and one presenting the investigational anti-CD37 radioimmunoconjugate 212Pb-NNV003, which is under evaluation in a research collaboration between Nordic Nanovector and Orano Med (formerly AREVA Med).
Cell Cycle Kinase Inhibitors Potentiate the Effect of 177Lu-lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma
Authors: G.R. Rødland et al.
Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
Authors: A. Saidi et al.
The abstracts will be published on 1 November 2018 at 09:00am Eastern time at http://www.hematology.org/Annual-Meeting/
For further information, please contact:
VP Investor Relations and Corporate Communications
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector